CureVac Establishes U.S. Operations in Cambridge, MA
The expansion into the U.S. extends the company’s footprint into one of the world’s preeminent biotechnology hubs. The US subsidiary will be headed by Karen Slobod, MD,as managing director, formerly Head of the Maternal Immunization Franchise at NovartisVaccines, and will primarily focus on development activities involving CureVac’s rapidly growing pipeline of mRNA-based prophylactic vaccines, which include programs targeting Rotavirus, RSV, HIV, and influenzavirusin collaborations with the Bill & Melinda Gates Foundation, IAVI and Johnson & Johnson. Additionally, the U.S. operations will enable CureVac to more directly engage the U.S. pharmaceutical and investor communities.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.